Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Novartis Successfully Demonstrates Capabilities Of Cell-based Technology For Production Of A(H1N1) Vaccine
Novartis has successfully completed the production of the first batch of influenza A(H1N1) vaccine, weeks ahead of expectations. Cell-based manufacturing technology[1] allows vaccine production to be initiated once a pandemic virus strain is identified without the need to adapt the virus strain to grow in eggs, as with traditional vaccine technologies. This advance has cut weeks off the time required to begin vaccine production. This first batch of ten liters of wild type influenza A(H1N1) vaccine monobulk will be used for pre-clinical evaluation and testing and is also being considered for use in clinical trials. It demonstrates the value of the cell-based production approach, that is also being used by Novartis with reassortant influenza A(H1N1) seed.

Potential Key To Maintaining Embryonic Stem Cells In Lab
In a new study that could transform embryonic stem cell (ES cell) research, scientists at UT Southwestern Medical Center have discovered why mouse ES cells can be easily grown in a laboratory while other mammalian ES cells are difficult, if not impossible, to maintain.
News of the day
AGTC And National Neurovision Research Institute Collaborate, Funding Research In Two Genetic Retinal Diseases
Applied Genetic Technologies Corporation (AGTC), a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that AGTC has entered into an agreement with the National Neurovision Research Institute (NNRI), the clinical trial support organization for the Foundation Fighting Blindness(FFB), to collaborate in experiments using the AAV delivery system in the treatment of two genetic retinal diseases known to cause blindness at an early age. The research will be coordinated by AGTC and will be conducted at The University of Florida, Oregon Health & Science University, The University of Pennsylvania, and The University of British Columbia.
Diagnostics

Media Examines U.S. Government's Steps To Lift HIV Travel Ban

The New York Daily News on Friday examined the federal government"s recent actions to remove HIV from the list of diseases that can bar foreign residents from entry into the U.S. According to the Daily News, "The current regulations took effect in 1987, at the height of the worldwide AIDS scare," but, "[n]ow, with the backing of the Obama administration, the ban could be lifted by the end of the year." Martin Cetron, director of the CDC"s Division of Global Migration and Quarantine, said, "We"re trying to end the stigma and the discriminatory practice for a disease that doesn"t warrant exclusion for coming into this country." MSNBC.com reports that "immigration critics say they"re leery of the proposal that could allow an average of 4,275 HIV-infected people into the country annually, with a lifetime medical cost of about $94 million for those admitted during the first year, according to CDC estimates published this month in the Federal Register" (Aleccia, 7/17). Through Aug. 17, CDC is seeking public comment on the proposed rule to remove HIV from the list of diseases that can bar entry into the U.S. (Miller, 7/17). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009